| [1] |
Deininger M,Buchdunger E,Druker BJ,et al.The development of imatinib as a therapeutic agent for chronic myeloid leukemia[J].Blood,2005,105(7):2 640-2 653.
|
| [2] |
Buchdunger E,Matter A,Druker BJ,et al.Bcr-Abl inhibition as a modality of CML therapeutics[J].BiochimBiophys Acta,2001,1 551(1):1-11.
|
| [3] |
Sawyers CL,Hochhaus A,Feldman E,et al.Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis:results of a phase II study[J].Blood,2002,99(10):3 530-3 539.
|
| [4] |
Ottmann OG,Druker BJ,Sawyers CL,et al.A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemia[J].Blood,2002,100(6):1 965-1 971.
|
| [5] |
Gorre ME,Mohammed M,Ellwood K,et al.Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification[J].Science,2001,293(5531):876-880.
|
| [6] |
Shah NP,Tran C,Lee FY,et al.Overriding imatinib resistance with a novel ABL kinase inhibitor[J].Science,2004,305(5 682):399-401.
|
| [7] |
Weisberg E,Manley PW,Breitenstein W,et al.Characterization of AMN107,a selective inhibitor of native and mutant Bcr-Abl[J].Cancer cell,2005,7(2):129-141.
|
| [8] |
Cortes JE,Kantarjian H,Shah NP,et al.Ponatinib in refractory Philadelphia chromosome-positive leukemias[J].N Engl J Med,2012,367(22):2 075-2 088.
|
| [9] |
Khorashad JS,Kelley TW,Szankasi P,et al.BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML:frequency and clonal relationship[J].Blood,2013,121(3):489-498.
|
| [10] |
Perrotti D,Neviani P.Resetting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukemia[J].Br J Cancer,2006,95(7):775-781.
|
| [11] |
Neviani P,Santhanam R,Trotta R,et al.The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein[J].Cancer cell,2005,8(5):355-368.
|
| [12] |
Christensen DJ,Chen Y,Oddo J,et al.SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma:a predictor of aggressive disease and a new treatment target[J].Blood,2011,118(15):4 150-4 158.
|
| [13] |
Yang Y,Huang Q,Lu Y,et al.Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation[J].J Cell Biochem,2012,113(4):1 314-1 322.
|
| [14] |
Saddoughi SA,Gencer S,Peterson YK,et al.Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis[J].EMBO Mol Med,2013,5(1):105-121.
|
| [15] |
Cristobal I,Garcia-Orti L,Cirauqui C,et al.PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect[J].Leukemia,2011,25(4):606-614.
|
| [16] |
Mukhopadhyay A,Saddoughil SA,Song P,et al.Direct interaction between the inhibitor 2 and ceramid via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling[J].FASEB J,2009,23(3):755-763.
[17] Christensen DJ,Ohkubo N,Oddo J,et al.Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A[J].J Immunol,2011,186(4):2 535-2 542.
|
| [17] |
Switzer CH,Cheng RY,Vitek TM,et al.Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy[J].Oncogene,2011,30(22):2 504-2 513.
|
| [18] |
Switzer CH,Cheng RY,Vitek TM,et al.Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia[J].Clin Cancer Res,2014,20(8):2 092-2 103.
|
| [19] |
Tukhovskaya EA,Yukin AY,Khokhlova ON,et al.COG1410,a novel apolipoprotein-E mimetic,improves functional and morphological recovery in a rat model of focal brain ischemia[J].J Neurosci Res,2009,87(3):677-682.
|
下载:
